中药芦根治疗急性呼吸道感染:随机对照试验的系统评价与Meta分析
该系统评价纳入42项RCT共6879例急性呼吸道感染患者,评估芦根制剂(均作为复方成分)的疗效与安全性。与安慰剂或常规治疗相比,芦根制剂可能提高治愈率、缩短退热时间并改善肺功能,但证据确定性低或极低,结论尚不确定。
要点
- 芦根制剂(作为复方成分)可能提高急性呼吸道感染治愈率(RR约1.55~1.60)。
- 芦根制剂可能缩短退热时间并改善FEV1和FVC,但证据确定性低或极低。
- 多数试验(38/42)为高偏倚风险,结论需严谨设计试验证实。
核心结论
- 低或极低确定性证据提示芦根制剂可能改善急性呼吸道感染治愈率、缩短发热患者退热时间并改善慢阻肺急性加重或慢性支气管炎患者肺功能。
- 上述发现尚不确定,需严谨设计的试验证实。
研究设计与样本
- 系统评价与Meta分析,检索8个数据库和2个临床试验注册库至2023年2月8日,纳入42项RCT共6879例急性呼吸道感染患者。
- 所有试验均评估芦根作为复方成分的制剂,采用RoB 2.0评估偏倚风险,RevMan 5.3进行数据分析,GRADEpro评估证据确定性。
主要发现
- 与安慰剂相比,芦根制剂提高治愈率[RR=1.60, 95%CI(1.13,2.26)]并缩短退热时间[MD=-2.73 h, 95%CI(-4.85,-0.61)]。
- 与单纯常规治疗相比,芦根制剂提高治愈率[RR=1.57, 95%CI(1.36,1.81)]并缩短退热时间[SMD=-1.24, 95%CI(-2.37,-0.11)]。
- 芦根制剂加常规治疗对比单纯常规治疗,提高治愈率[RR=1.55, 95%CI(1.35,1.78)]、缩短退热时间[MD=-19.31 h, 95%CI(-33.35,-5.27)]、改善FEV1[MD=0.19 L, 95%CI(0.13,0.26)]和FVC[MD=0.16 L, 95%CI(0.03,0.28)]。
- 纳入试验多数(38/42)为高偏倚风险。
关键数值与推荐
- 治愈率:与安慰剂比RR=1.60(95%CI 1.13~2.26);与常规治疗比RR=1.57(95%CI 1.36~1.81);加常规治疗比RR=1.55(95%CI 1.35~1.78)。
- 退热时间:与安慰剂比MD=-2.73 h(95%CI -4.85~-0.61);与常规治疗比SMD=-1.24(95%CI -2.37~-0.11);加常规治疗比MD=-19.31 h(95%CI -33.35~-5.27)。
- 肺功能:加常规治疗对比常规治疗,FEV1 MD=0.19 L(95%CI 0.13~0.26),FVC MD=0.16 L(95%CI 0.03~0.28)。
- 证据确定性为低或极低。
临床怎么用
- 在急性呼吸道感染治疗中,可考虑将芦根作为复方成分联合常规治疗,可能有助于提高治愈率并缩短退热时间。
- 对慢阻肺急性加重或慢性支气管炎患者,芦根复方可能改善肺功能,但需结合临床谨慎评估。
- 因证据确定性低且多数试验高偏倚风险,不宜单独依据本结论改变临床实践,应个体化决策。
局限性
- 所有纳入试验均评估芦根作为复方成分,无法区分芦根单味药的独立效应。
- 多数试验(38/42)为高偏倚风险,证据确定性低或极低。
- 结论尚不确定,需严谨设计的随机对照试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Acute respiratory tract infections (ARTIs) are the most common cause of morbidity and mortality worldwide, with most people experiencing at least one episode per year. Current treatment options are mainly symptomatic therapy. Antivirals, antibiotics, and glucocorticoids are of limited benefit for most infections. Traditional Chinese medicine has shown potential benefits in the treatment of ARTIs. Objective: The objective of this study was to determine the efficacy, effectiveness, and safety of Phragmites communis Trin. (P. communis, a synonym of Phragmites australis (Cav.) Trin. ex Steud) as monotherapy or as part of an herb mixture for ARTIs. Method: Eight databases and two clinical trial registries were searched from inception to 8 February 2023 for randomized controlled trials (RCTs) evaluating any preparation involving P. communis without language restrictions. The Risk of Bias Tool 2.0 was used to assess the risk of bias of the included trials. RevMan 5.3 software was used for data analyses with effects estimated as risk ratios (RRs), mean differences (MDs), or standardized mean differences (SMDs) with 95% confidence intervals (CIs). The online GRADEpro tool was used to assess the certainty of the evidence, if available. Results: Forty-two RCTs involving 6,879 patients with ARTIs were included, with all trials investigating P. communis as part of an herbal mixture. Of the included trials, the majority (38/42) were considered high risk. Compared to the placebo, P. communis preparations improved the cure rate [RR = 1.60, 95% CI (1.13, 2.26)] and fever clearance time [MD = -2.73 h, 95% CI (-4.85, -0.61)]. Compared to usual care alone, P. communis preparations also significantly improved the cure rate [RR = 1.57, 95% CI (1.36, 1.81)] and fever clearance time [SMD = -1.24, 95% CI (-2.37, -0.11)]. P. communis preparations plus usual care compared to usual care alone increased the cure rate [RR = 1.55, 95% CI (1.35, 1.78)], shortened the fever clearance time [MD = -19.31 h, 95% CI (-33.35, -5.27)], and improved FEV1 [ MD = 0.19 L, 95% CI (0.13, 0.26)] and FVC [ MD = 0.16 L, 95% CI (0.03, 0.28)]. Conclusion: Low- or very low-certainty evidence suggests that P. communis preparations may improve the cure rate of ARTIs, shorten the fever clearance time in febrile patients, and improve the pulmonary function of patients with acute exacerbation of chronic obstructive pulmonary disease or chronic bronchitis. However, these findings are inconclusive and need to be confirmed in rigorously designed trials. Systematic review registration: PROSPERO, identifier CRD42021239936.
引用
- Fang M, Kong LY, Ji GH, et al. Chinese medicine Phragmites communis (Lu Gen) for acute respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2024. PMID: 38510651. doi:10.3389/fphar.2024.1242525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。